2,207 reports of this reaction
1.6% of all TRAMADOL HYDROCHLORIDE reports
#9 most reported adverse reaction
DYSPNOEA is the #9 most commonly reported adverse reaction for TRAMADOL HYDROCHLORIDE, manufactured by Vertical Pharmaceuticals, LLC. There are 2,207 FDA adverse event reports linking TRAMADOL HYDROCHLORIDE to DYSPNOEA. This represents approximately 1.6% of all 142,038 adverse event reports for this drug.
TRAMADOL HYDROCHLORIDE has an overall safety score of 85 out of 100. Patients taking TRAMADOL HYDROCHLORIDE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for TRAMADOL HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for TRAMADOL HYDROCHLORIDE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 2,207 FDA reports for TRAMADOL HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 1.6% of all adverse event reports for TRAMADOL HYDROCHLORIDE, making it a notable side effect.
If you experience dyspnoea while taking TRAMADOL HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.